Carbapenem Use Is Driving the Evolution of Imipenemase 1 Variants-Reference-Cited by-同舟云学术

Carbapenem Use Is Driving the Evolution of Imipenemase 1 Variants

Published:2021-03-18 Issue:4 Volume:65 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Cheng Zishuo¹^ORCID,Bethel Christopher R.²,Thomas Pei W.³,Shurina Ben A.¹,Alao John-Paul¹,Thomas Caitlyn A.¹,Yang Kundi¹,Marshall Steven H.²,Zhang Huan¹,Sturgill Aidan M.¹,Kravats Andrea N.¹,Page Richard C.¹^ORCID,Fast Walter³^ORCID,Bonomo Robert A.²⁴⁵⁶⁷^ORCID,Crowder Michael W.¹^ORCID

Affiliation:

1. Department of Chemistry and Biochemistry, Miami University, Oxford, Ohio, USA

2. Research Services, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA

3. Division of Chemical Biology and Medicinal Chemistry, College of Pharmacy, and the LaMontagne Center for Infectious Disease, University of Texas, Austin, Texas, USA

4. Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA

5. Department of Pharmacology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA

6. Department of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA

7. Department of Biochemistry, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA

Abstract

Metallo-β-lactamases (MBLs) are a growing clinical threat because they inactivate nearly all β-lactam-containing antibiotics, and there are no clinically available inhibitors. A significant number of variants have already emerged for each MBL subfamily.

Funder

Robert A. Welch Foundation

HHS | National Institutes of Health

HHS | NIH | National Institute of Allergy and Infectious Diseases

Geriatric Research Education and Clinical Center VISN 10

Biomedical Laboratory Research and Development Service of the VA Office of Research and Development

U.S. Department of Veterans Affairs

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01714-20

Reference72 articles.

1. Antibiotics and Bacterial Resistance in the 21st Century

2. CDC. 2019. More people in the United States dying from antibiotic-resistant infections than previously estimated. https://www.cdc.gov/media/releases/2019/p1113-antibiotic-resistant.html. Accessed March 19th 2020.

3. β-Lactams and β-Lactamase Inhibitors: An Overview

4. β-Lactamases and β-Lactamase Inhibitors in the 21st Century

5. Past and Present Perspectives on β-Lactamases

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The interaction of the azetidine thiazole side chain with the active site loop (ASL) 3 drives the evolution of IMP metallo-β-lactamase against tebipenem;Antimicrobial Agents and Chemotherapy;2024-08-07

2. Colistin Resistance Mediated by Mcr-3-Related Phosphoethanolamine Transferase Genes in Aeromonas Species Isolated from Aquatic Environments in Avaga and Pakro Communities in the Eastern Region of Ghana;Infection and Drug Resistance;2024-07

3. Tackling Carbapenem Resistance and the Imperative for One Health Strategies—Insights from the Portuguese Perspective;Antibiotics;2024-06-14

4. Machine Learning Models Identify Inhibitors of New Delhi Metallo-β-lactamase;Journal of Chemical Information and Modeling;2024-05-10

5. Relative inhibitory activities of the broad-spectrum β-lactamase inhibitor xeruborbactam in comparison with taniborbactam against metallo-β-lactamases produced in Escherichia coli and Pseudomonas aeruginosa;Antimicrobial Agents and Chemotherapy;2024-05-10